Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Statute of Limitations for Tysabri in North Carolina

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Pharmaceutical Risks

For decades, general health and science information has served as the foundation for public understanding of medical treatments and their potential long-term consequences. This broad educational framework has enabled individuals to recognize that therapeutic interventions, while beneficial for many, may carry inherent risks that require careful monitoring. Within this legacy context, the focus has been on empowering patients with knowledge about drug mechanisms, side effect profiles, and the importance of informed consent in clinical decision-making. As this informational heritage evolves, a more targeted concern has emerged regarding specific pharmaceutical exposures and their occupational implications. One such area involves the medication Tysabri, used in the treatment of certain chronic conditions, and its association with Progressive Multifocal Leukoencephalopathy (PML)—a rare but serious brain infection. For individuals in North Carolina who have been prescribed Tysabri and subsequently developed PML, questions of legal recourse and accountability arise. The statute of limitations for filing a claim related to Tysabri exposure in North Carolina is a critical factor that affected individuals must consider when seeking legal representation. This transition from general health awareness to specific occupational exposure concern underscores the need for specialized legal guidance in navigating the complexities of pharmaceutical injury claims within the state’s legal framework.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic medication approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the John Cunningham virus (JCV). The FDA-approved prescribing information includes a boxed warning stating that Tysabri increases the risk of PML, which usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing surveillance. The mechanism linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing latent JCV to reactivate and cause lytic infection of oligodendrocytes. The prescribing information identifies three key risk factors for PML: the presence of anti-JCV antibodies, longer duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefit when initiating or continuing treatment.

Clinical Presentation and Diagnosis of PML

Clinical presentation of PML typically includes subacute neurological deficits such as cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via PCR. The prescribing information advises healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, PML often progresses rapidly, leading to permanent disability or death. The timeline between Tysabri exposure and documented harm varies. FAERS adverse-event reports show that Tysabri is associated with a range of neurological symptoms, including fatigue, gait disturbance, memory impairment, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These reports do not specify PML onset timing, but clinical studies indicate that PML risk increases with cumulative exposure, particularly after 24 months of treatment.

Legal Considerations for North Carolina Patients

For affected patients in North Carolina, attorney-related considerations include the statute of limitations for filing a product liability claim. In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For PML, this discovery date may be when symptoms first appear or when a definitive diagnosis is made. Given the latency of PML, patients may not recognize the connection to Tysabri until months or years after exposure. Attorneys must carefully document the timeline between Tysabri administration, onset of neurological symptoms, and PML diagnosis to establish when the statute of limitations began. Risk anchors for attorneys also include evaluating whether the prescribing physician adequately warned the patient about PML risks and whether the patient's informed consent was valid. The TOUCH program requires documentation of risk discussion, but lapses in this process could support a failure-to-warn claim. Additionally, the severity of PML outcomes—death or severe disability—may influence damages calculations. Attorneys should review medical records for evidence of anti-JCV antibody testing, duration of Tysabri therapy, and any prior immunosuppressant use, as these factors are central to risk assessment.

Adequacy of Warnings and Regulatory Context

Adequacy of warnings regarding Tysabri and PML is a central issue. The boxed warning is prominently displayed, and the drug is only available through the restricted TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, some patients and attorneys argue that these warnings may not fully convey the magnitude of risk or the potential for irreversible harm, especially in patients without recognized risk factors. The prescribing information states that Tysabri should not be used with immunosuppressants or TNF-alpha inhibitors in Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), but prior immunosuppressant use remains a risk factor for PML.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in North Carolina?

In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For PML, this discovery date may be when symptoms first appear or when a definitive diagnosis is made. Given the latency of PML, patients may not recognize the connection to Tysabri until months or years after exposure, so prompt legal evaluation after diagnosis is critical.

What are the key risk factors for developing PML while on Tysabri?

The prescribing information identifies three key risk factors for PML: the presence of anti-JCV antibodies, longer duration of therapy (especially after 24 months), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefit when initiating or continuing treatment.

How is PML diagnosed in patients who have taken Tysabri?

Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via PCR. Clinical presentation typically includes subacute neurological deficits such as cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Healthcare professionals are advised to monitor for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.